Search Results 651-660 of 18042 for Alopecia

1. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

   Clinically significant toxicity (other than alopecia) from prior therapy that has not resolved to Grade ≤ 1 (according to the NCI CTCAE, v4.0) prior to Day 1 ...

2. A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects - Mayo Clinic

   0], with the exception of persistent alopecia, adrenal insufficiency, and hypothyroidism) due to prior treatment. Active pneumonitis, history of pneumonitis ...

3. Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) - Mayo Clinic

   Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy. Subject must ...

4. Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy - Mayo Clinic

   ... alopecia, anemia and any signs or symptoms of androgen deprivation therapy); Willing to provide tissue and blood samples for correlative research purposes ...

5. Albinism - Symptoms and causes - Mayo Clinic

   In this group of inherited disorders, the body makes little or no melanin, a pigment that determines hair, skin and eye color and vision development.

6. Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas - Mayo Clinic

   ... alopecia, fatigue, and hematologic toxicities); Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to ...

7. Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...

8. https://www.mayoclinic.org/chinese_organization_concepts.xml

9. A Study of MCLA-128 in Patients with Solid Tumors Harboring an NRG1 Fusion - Mayo Clinic

   03) except for alopecia, Grade 2 sensory neurotoxicity, or any other toxicity that in the opinion of the Investigator does not affect the assessment of ...

10. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

    ... alopecia; Radiation therapy within ≤ 14 days; Active or untreated brain metastases; History of carcinomatous meningitis; Uncontrolled concurrent malignancy ...